What is Secukinumab?

Category: Prescription Drugs

Most popular types: Cosentyx

false

Secukinumab is type of immunosuppressant that helps in the treatment of psoriasis.

Reported purpose & perceived effectiveness
Purpose Patients Evaluations Perceived Effectiveness
Psoriatic arthritis 11 6
Psoriatic plaques (scaly patches) 11 7
Ankylosing spondylitis 2 0
Palmoplantar pustulosis 1 0

  • Major
  • Moderate
  • Slight
  • None
  • Can't tell

Side effects

Side effects as an overall problem

Side effects as an overall problem
Severity Evaluations
Severe 0
Moderate 0
Mild 1
None 8

Commonly reported side effects and conditions associated with Secukinumab

Side effect Patients
Upset stomach 1

Dosages

Based on patients currently taking Secukinumab

Dosage Patients
300 mg monthly 3
150 mg weekly 3
150 mg every other week 1
300 mg weekly 1
22,500 mg monthly 1

Why patients stopped taking Secukinumab

Multiple reasons could be selected

Reason Patients
Change in health plan coverage 1
Did not seem to work 1
See all 2 patients who've stopped taking Secukinumab

Duration

Currently taking Secukinumab

Duration Patients
1 - 6 months 3
6 months - 1 year 1
1 - 2 years 4
2 - 5 years 1

Stopped taking Secukinumab

Duration Patients
1 - 6 months 1
1 - 2 years 1
Adherence
Adherence Evaluations
Always 7
Usually 1
Sometimes 0
Never taken as prescribed 1
Burden
Burden Evaluations
Very hard to take 0
Somewhat hard to take 0
A little hard to take 2
Not at all hard to take 7
Cost per month
Cost per month Evaluations
$200+ 0
$100-199 0
$50-99 1
$25-49 0
< $25 6
Not specified 2

What people switch to and from

Patients started taking Secukinumab after stopping:

Treatment Patients
Apremilast (Otezla) 4
Adalimumab (Humira) 3
Infliximab (Remicade) 3
Ustekinumab (Stelara) 3
Clobetasol topical (Clobex) 1

Show all 10 treatments patients report switching from

Patients stopped taking Secukinumab and switched to:

Treatment Patients
Dimethyl fumarate (Tecfidera) 1
Infliximab (Remicade) 1
Last updated:
There are no evaluations for Secukinumab.